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Abstract
Objectives: To determine changes in neuromuscular performance throughout the menstrual cycle in females aged
18-25. Methods: Fifty physically active college females (25 on oral contraceptives (OC)) were recruited to participate.
Data collection visits coincided with early-follicular (Fp), ovulatory (Op), and the mid-luteal (Lp) phases. Isokinetic peak
torque at the knee (IPT) was measured at 60°/sec, 180°/sec, and 300°/sec. Grip force was measured using a handheld
dynamometer. Plasma estradiol and progesterone confirmed menstrual cycle and serum relaxin was screened as a
potential covariate. Results: Grip strength was lower during Fp (30.1±0.7kg) than during Op (31.5±0.7 kg, p=0.003) and
Lp (32.6±0.7 kg, p<0.001). IPT at 60°/sec was lower during Fp (83±14 nM) than during the Op (86±15 nM, p=0.02).
IPTs at 180°/sec and 300°/sec were lower during Fp than Op and Lp (180°:54±10 vs. 58±10 and 61±11 nM [both,
p<0.001]; 300°: 43±9 vs. 46±9 and 47±9 nM [both<0.001]. The OC group-by-phase interaction was not significant for
any of the outcomes. Conclusions: Results indicate that muscular performance is diminished during Fp and the lack of
group-by-phase interaction indicates that this effect is not hormone-related. These data indicate that females may be at a
greater risk of injury due to decreased strength during Fp than other phases of their cycle.
Keywords: ACL, Female, Grip, Isokinetic, Menstrual

Introduction
Lower extremity injuries are a serious concern in the
military, athletic, and other physically active populations1-3.
Anterior cruciate ligament (ACL) injuries are of particular
interest because of the significant loss of training time and
potential for long-term complications such as post-traumatic
osteoarthritis4. When controlling for competitive level, female
athletes appear to be at a greater risk for ACL injuries than
male athletes5. Ireland et al. reported that female basketball
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players tear their ACL at almost three times the rate of men6.
The discrepancy may be even larger in military training with
one study reporting a relative risk of 9.74 per 1000 athleteexposures for ACL injury for females compared to males7.
These discrepancies necessitate further investigation into
potential mechanisms for the greater incidence of ACL
injuries in females with the goal of developing sex-specific
prevention protocols.
While many mechanisms have been suggested, prior
studies indicate that the increased risk is a function of
musculoskeletal and hormonal risk factors8-11. Muscle force
production is a key factor in reducing the risk of ACL injuries
due to the stabilizing role of the quadriceps and hamstrings
at the knee. Females have been reported to have weaker
hamstrings than males12 and a lower hamstring-to-quadriceps
strength ratio8 may increase their risk of non-contact knee
injuries13. Additionally, greater knee joint laxity in females
has been suggested as a potential reason for the disparity
in injury rates between males and females12,14. Greater knee
joint laxity would theoretically result in excessive motion
314
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about the joint, thereby increasing the risk that forces on the
ligament may exceed its yield point. However, several studies
with small sample sizes and inconsistent methodology
have investigated changes in knee joint laxity throughout
the menstrual cycle with different studies indicating an
association between knee joint laxity and menstrual cycle
phases and some studies showing no association15-18.
Fluctuations in female sex hormones, combined with the
proposed relationship of these hormones to joint laxity6,9,
suggest that injury rates may fluctuate based on hormonal
changes that occur throughout the menstrual cycle. Prior
studies have reported that estrogen receptors are present
in human ACL and skeletal muscle tissue and that fibroblast
metabolism, myoblast growth, and collagen synthesis are all
altered in the presence of estrogen19-21. The specific effects
of estrogen on skeletal muscle have been studied extensively
in post-menopausal women with one large meta-analysis
reporting a beneficial effect of estrogen-based hormone
replacement therapy on muscle strength22. While the
underlying mechanism is not well understood, these studies
suggest that as estrogen fluctuates throughout the menstrual
cycle so might muscle force production and joint laxity. If this
is the case, hormonal contraception could be associated with
injuries by limiting the hormonal fluctuations and subsequent
fluctuations in joint laxity and muscle function that occur
during the cycle23. This is supported by previous studies
investigating the association between ACL injury risk and
contraceptive use that have indicated a protective effect of
oral contraceptives on injury risk24,25.
Relaxin is a hormone that is responsible for connective
tissue changes late in pregnancy to accommodate childbirth.
Due to its effect of reducing stiffness of tendons and
ligaments, it is hypothesized that an increase in relaxin
concentration could result in a decrease of force production
as well as increased joint laxity. With the presence of relaxin
specific binding sites on connective tissue in females, the
mechanism exists for relaxin to act on these tissues26,27.
This theoretical framework is supported by the results of
a longitudinal investigation that found that an increase in
serum relaxin concentration over 6 pg/mL was associated
with a fourfold increase in ACL tears28.
Previous studies have suggested that a potential
relationship may exist between menstrual cycle phase
and ACL injury risk; however, the results of these studies
are inconclusive with injury risk being reported as highest
during each of the three phases in at least one study9,29-31.
While extensive progress has been made in the area of sex
differences in the risk of ACL injuries, much of the data
have been inconclusive. The purpose of this study was to
investigate changes in muscular strength and stamina, and
joint laxity throughout the menstrual cycle and to determine
how oral contraceptive (OC) use alters these findings. We
hypothesized that changes in isokinetic peak torque, grip
strength, and joint laxity over the menstrual cycle phases
would be greater in the non-OC group than the OC group due
to greater variablitily in hormone concentrations.
http://www.ismni.org

Methods
Participant information
Physically active females aged 18 to 25 years old (n=50)
were recruited from South Dakota State University through
on-campus advertising and through meetings with classes
in the Health and Nutritional Sciences Department. Twentyfive females who were taking OCs (monophasic) and twentyfive women that were not taking OC were recruited. Three
participants in the non-OC group who did not ovulate, and
one participant in the OC group who was missing hormone
measurements, were excluded from all analyses. The South
Dakota State University Institutional Review Board approved
this protocol and informed consent was obtained from all
participants prior to the study. On the day of the initial visit,
participants completed a physical activity readiness screening
(PAR-Q) and filled out a health history questionnaire that
included the number of days that they perform at least 30
minutes of structured physical activity per week.
Inclusion and exclusion criteria
An initial questionnaire was administered to determine
whether the menstrual cycle of potential participants was
regular (every 21-35 days) and only those individuals with
a regular menstrual cycle were invited to participate. In
addition to cycles occurring every 21-35 days, menstrual
regularity also included that participants had experienced
menstrual bleeding in each of the past 3 months. For the OC
group, only women who had been taking a monophasic OC
for a minimum of 3 months prior to the study were invited
to participate. Participants were excluded if they were using
alternative contraception methods including vaginal rings,
intrauterine devices, or injections. Participants were excluded
if they had suffered any injury to their lower extremity in the
past 6 months or had a previous ACL injury.
Visit schedule and bias reduction
Participants completed three visits that were designed to
coincide with the early-follicular, ovulatory, and mid-luteal
phases of the menstrual cycle (Table 1). All participants were
asked to contact the study coordinator on the first day of
their menstrual cycle to schedule an appointment for their
first testing session. This visit took place within 72 hours
of the onset of menses. Participants who were taking OCs
had their subsequent visit on cycle day 14 to 16 and their
final visit 1 week after their second visit. Participants who
were not taking OCs were asked to take a home ovulation
test every day beginning at day 7 which indicated when the
luteinizing hormone (LH) surge occurred prior to ovulation.
When a positive test occurred, the participants were asked
to contact the study coordinator and set up a visit within 48
hours of the positive test. The final visit took place 7 days
after the ovulation visit.
In order to decrease the effect of diurnal variability of
hormone concentrations on our results, all study visits
were scheduled in the morning and all follow-up visits were
315
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Figure 1. Positioning of the participant for isokinetic testing on the Biodex System 4 ergometer.

scheduled within 2 hours of the time that the early-follicular
phase visit was performed. Additionally, participants were
asked to refrain from moderate or vigorous physical activity
for 24 hours prior to the visit. Participants completed a 24hour diet record using the ASA 24 (NIH, National Cancer
Institute, Bethesda, MD) prior to each visit to ensure that
dietary factors that may influence grip strength or isokinetic
torque production were not different among visits. Finally,
participants were asked to complete a menstrual symptom
questionnaire at each visit to capture symptoms they may
experience that could be attributed to their menstrual
cycle. The instrument asked about musculoskeletal as well
as psychological symptoms that may occur throughout the
menstrual cycle.
Anthropometrics
Anthropometric measurements were taken in duplicate.
Height without shoes was measured to the nearest 0.5 cm
using a portable stadiometer (Seca Model 225). Weight was
measured to the nearest 0.1 kg using a digital scale (Seca
Model 770) with the participant wearing light clothing. Height
and weight were screened as covariates due to the potential
effect of body physique on muscle torque production.
Body composition
Dual-energy x-ray absorptiometry (DXA) scans were
completed using a Hologic Discovery-A scanner (Apex
Softward v.5.6, Hologic Inc., Bedford, MA). Our measurements
of lean and fat mass are precise with percent coefficients of
http://www.ismni.org

variation of 0.4% and 1.3%, respectively. Lean and fat mass
may be correlated with measures obtained from Biodex
testing and therefore were considered as potential covariates.
Grip strength
Grip strength of the dominant side was measured using the
digital Grip-D grip strength dynamometer (Takei Scientific
Instruments, Niigata-City, Japan). We adjusted the apparatus
to the proper hand size for each participant. The participant
then held the dynamometer with their arm relaxed and
extended downward and squeezed the instrument as hard as
possible for three seconds. This test was repeated two more
times and the highest reading of the three trials was recorded.
Data from a previously performed reliability study in our lab
indicates that no significant learning effect is present when
three testing sessions are performed over the course of 30
days. The coefficient of variation for grip strength among the
three visits was 4.4%.
Isokinetic testing
Isokinetic testing was performed using a Biodex System
4 (Biodex Medical Systems, Shirley, NY). Participants were
seated with their shoulders and waist strapped to the chair
(Figure 1). Following the manufacturer’s recommendation,
the dynamometer was oriented at 90o with a 0o tilt. The
seat was set at 85o tilt with the axis of rotation at the knee
set to pass through the lateral femoral condyle in a sagittal
plane. The participant’s distal lower leg was secured using
Velcro strap positioned immediately proximal to the medial
316
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Table 1. Data collected at each visit.
Procedure
Informed Consent
Health History Questionnaire
Menstrual Symptom
Questionnaires
Body Composition
Anthropometrics
Venipuncture
Isokinetic Testing
Laxity Testing
Fatigue Protocol

Early Follicular
X
X

Ovulation

Mid Luteal

X

X

X

X
X
X
X
X
X

X
X
X
X

X
X
X
X

malleolus. Prior to beginning the testing, the participant was
instructed to grab each of the side handles for support. Once
the participant was properly positioned, they went through a
series of 5 to 7 familiarization repetitions to get accustomed
to the machine. The first 3 to 5 repetitions were done at very
low effort with the final 2 repetitions being performed at
100% effort. Familiarization repetitions were performed at
every testing session to ensure that participants were tested
similarly across all visits. The performance trial consisted of
5 isokinetic knee extension and knee flexion repetitions at
60o/second, 5 repetitions at 180o/second, and 5 repetitions
at 300o/second. Each series of repetitions were separated
by a one-minute rest period. Standardized feedback was
given to every participant reminding them to complete
the testing with maximal efforts. This feedback was given
during the flexion phase of repetition two. The Biodex has
been reported to be a reliable tool for measuring isokinetic
torque production up to 300o/second (ICC=0.99, CV<2%)32.
In addition to peak torque measurements, isokinetic testing
was used to determine the knee flexor-to-knee extensor
ratio. Data from a previously performed reliability study in
our lab indicate that no effect of study visit order when three
testing sessions were performed over the course of 30 days.
The coefficients of variation among the three study visits
at 60o, 180o, and 300o/sec were 6.8%, 5.8% and 6.2%,
respectively (Supplemental Table 1).

Knee joint laxity

Fatigue protocol

Estradiol-17

A fatigue protocol was utilized to examine whether or not
individuals fatigued at a different rate at different phases of the
menstrual cycle. The fatigue test was performed a minimum
of 30 minutes after the initial isokinetic testing and consisted
of participants performing a number of repeated maximal leg
extension and flexion movements at 180o per second using
the Biodex. The participant was considered “fatigued” when
they performed three consecutive repetitions in which their
peak torque in both extension and flexion were less than
50% of the peak torque measured during the non-fatigued
isokinetic testing.

Plasma concentrations of estradiol (E2) were determined
in duplicate by radioimmunoassay (RIA). Estradiol-17
(E8875; Sigma Life Science, St. Louis, MO) was the standard
and radioiodinated E2 (#07138228; MP Biomedicals, Solon,
OH) was the tracer. Antisera (GDN#244 anti-estradiol-17
6-BSA; Fort Collins, CO) was used at a dilution of 1:425,000.
Sera (250-L) was extracted with a 4-mL volume of methyl
tert-butyl ether. Recovery of [125I]estradiol-17 added to
plasma before extraction averaged 96±2%. Inhibition curves
of increasing amounts of sample were parallel to standard
curves. Intra- and inter-assay coefficients of variation were

http://www.ismni.org

Knee joint laxity was measured using the KT 1000 knee
arthrometer with the participant lying in a comfortable
supine position. An adjustable thigh support platform was
placed under both legs just proximal to the popliteal space.
A foot support platform was placed under both feet with the
patient’s feet located in a position that allows the knee to
be in a neutral position. All of these tests were done prior
to (rested) and immediately following the Biodex testing
(fatigued) to assess the effect of thigh fatigue on knee joint
laxity. The same certified athletic trainer performed all knee
joint laxity measurements. A reliability study was performed
prior to the start of the study and a percent coefficient of
variation of 4.3% was calculated for this examiner.
Blood collection procedure
Blood was collected by a trained phlebotomist prior to any
physical measurements taking place. The participant was
placed in a seated position with their feet flat on the floor and
their arm lying on the collection table. The phlebotomist used
a BD Vacutainer blood collection kit (Becton, Dickinson and
Company, Franklin Lakes, NJ) to collect the sample from a
vein in the antecubital region. A total of 17 ml of blood was
collected into a 10ml serum separation tube and a 7 ml tube
with K3 EDTA additive.
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Table 2. Participant characteristics.
Non-OC (n=22)a
OC (n=24)b
P-Value
Height (cm)
167.0 ± 6.5
169.9 ± 7.0
NS
Lean Mass (kg)
45.3 ± 4.8
45.1 ± 5.9
NS
Fat Mass (kg)
18.5 ± 5.6
20.6 ± 6.8
NS
Age (years)
20 ± 1
20 ± 1
NS
Phys. Act. (day/wk)
5.0 ± 1.5
4.6 ± 1.5
NS
Data are presented as mean ± SD. a3 participants did not ovulate and were excluded from all analyses. b1 participant did not have complete
data and was excluded from all analyses.

Figure 2. Marginal mean peak torque at 60o, 180o, and 300o per second (marginal mean ± SE). Data are marginal means after adjusting
for contraception group (not significant), lean mass, and fat mass. Data were compared within different test speeds using pairwise
comparisons using a Bonferroni adjustment.

12.8% and 12.6%, respectively. Sensitivity of the assay was
0.4 pg/tube.
Progesterone
Plasma concentrations of progesterone were determined
in duplicate by RIA. Progesterone (P0130; Sigma Life
Science; St. Louis, MO) was the standard and radioiodinated
progesterone (#07-170126; MP Biomedicals, Solon, OH) was
used as the tracer. Antisera (#111.2C7.3; Enzo Life Sciences,
Farmingdale, NY) was used at a dilution of 1:700,000.
Inhibition curves of increasing amounts of sample were
parallel to standard curves. Intra-assay coefficient of variation
was 8.0%. Sensitivity of the assay was 0.10 ng/tube.
Relaxin
Plasma concentrations of relaxin were determined in
duplicate by RIA using the Relaxin 2 kit (RK-035-62,
http://www.ismni.org

Phoenix Pharmaceutical, Inc, Burlington, CA) according to
the manufacturer’s directions. Inhibition curves of increasing
amounts of sample were parallel to standard curves. Intraassay coefficient of variation was 5.9%. Sensitivity of the
assay was 7.8 pg/tube.
Statistical analysis
Student’s t-tests were used to compare the baseline
characteristics of the OC and non-OC groups. Linear
mixed effects models were used to determine the effect
of menstrual cycle phase on dependent variables while
adjusting for covariates. Dependent variables included grip
strength, isokinetic peak torque, repetitions to fatigue, and
knee joint laxity. Independent variables that were tested
included the log of estrogen and relaxin concentrations,
menstrual cycle phase, and OC use. Covariates that were
screened included menstrual symptoms, lean mass, fat
mass, age, height, physical activity days, caloric intake,
318

L. Weidauer et al.: Neuromuscular performance changes throughout the menstrual cycle in physically active females

Table 3. Menstrual symptoms by phase and group.
Follicular
Ovulation
Luteal
NOC
OC
NOC
OC
NOC
OC
I feel more irritable than normal*
33%
21%
5%
0%
10%
4%
I am experiencing menstrual cramps*
38%
54%
0%
8%
0%
4%
I am feeling more depressed than normal
10%
4%
0%
0%
0%
0%
I am experiencing more stomach pain than normal*
33%
21%
5%
0%
10%
13%
I get tired more easily*
57%
33%
10%
4%
10%
21%
I am taking a prescription for menstrual pain
0%
4%
0%
4%
0%
4%
I am feeling weak or dizzy
0%
8%
0%
0%
10%
0%
I am feeling tense or nervous
5%
13%
5%
8%
19%
8%
I am experiencing diarrhea
14%
0%
0%
0%
5%
0%
I am experiencing backaches or lower back pain*
33%
33%
19%
8%
19%
8%
I am taking OTC medication for pain*
10%
13%
0%
0%
0%
0%
I am experiencing pain in my breasts
5%
13%
0%
0%
10%
0%
I am using heat to treat my abdominal or back pain
0%
8%
0%
4%
0%
0%
I am experiencing constipation
0%
0%
5%
0%
5%
4%
I am experiencing muscle spasms in my legs
0%
0%
0%
0%
0%
0%
I am feeling more bloated than normal*
53%
38%
5%
0%
19%
17%
I am feeling more nauseous than normal
14%
4%
0%
0%
5%
8%
I am having more headaches than normal
19%
8%
0%
4%
10%
8%
Data shown are the percentage of participants who responded “Yes” to each statement. NOC = No oral contraception. OC = Oral contraception.
Chi2 analysis revealed no between-group differences for any of the variables at any phase. *Indicates differences in the proportion of
menstrual symptoms experienced among phases (chi2, p<0.05).

macronutrient intake, and caffeine intake. To determine
whether or not changes throughout the menstrual cycle were
different between the OC and non-OC groups, a group-byphase interaction was used. Final models included OC use,
menstrual cycle phase, lean mass, and fat mass. Marginal
means were calculated and post-hoc comparisons were
performed using a Bonferroni adjustment with a=0.05. All
analyses were performed using STATA 15 (StataCorp. 2017.
Stata Statistical Software: Release 15. College Station, TX:
StataCorp LLC).

Grip strength

Results

Extension peak torque at 60o/sec was 4% lower during
the early-follicular visit (82.4±2.1 nM) than the ovulation
visit (85.7±2.1 nM; p<0.05), but was not different at the midluteal phase visit (84.7±2.1 nM) (Figure 2). Extension peak
torque at 180o was 8-11% lower at the early-follicular phase
(53.7±1.5 nM) than the ovulatory and mid-luteal phases
(58.1±1.5 nM and 60.4±1.5 nM, respectively; both, p<0.05).
Similarly, extension peak torque at 300o/sec was 7-8%
lower at the early-follicular phase (42.9±1.3 nM) than the
ovulatory and mid-luteal phases (46.3±1.3 nM and 46.6±1.3
nM, respectively; both p<0.05).
Flexion peak torque at 60o/sec was 8% lower at the
early-follicular visit than the ovulation visit (39.5±1.5
nM and 43.0±1.4 nM, respectively; p<0.05). Flexion peak
torque at 180o/sec also was 13-14% lower at the early-

Participant characteristics
Participant characteristics by OC group are given in
Table 2. Age, height, lean mass, fat mass, and physical
activity days per week at each visit did not differ between
groups. No differences between groups were observed
in the proportion of participants experiencing menstrual
symptoms at any of the visits; however, a greater proportion
of participants experienced menstrual symptoms during
the early-follicular phase than the ovulatory or luteal
phases in 7 out of 18 categories (Table 3). Total caloric
intake, protein intake, carbohydrate intake, and caffeine
intake 24 hours prior to each visit were not different
among visits (Table 4).
http://www.ismni.org

Grip strength was greater at the ovulation (31.5±4.1
kg) and mid-luteal visits (32.5±4.9 kg) than at the
early-follicular visit (30.0±4.4 kg). No group-by-phase
interaction was observed, indicating similar menstrual
phase differences for non-OC and OC users. Grip strength
was not different between the OC and non-OC group at any
visit (Supplemental Table 2).
Isokinetic testing, fatigue, and knee joint laxity
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Table 4. Dietary intakes, flexor to extensor ratio and knee joint laxity by cycle phase.
Early-Follicular
Ovulatory
Mid-Luteal
Caloric Intake (Kcal)
2180 ± 1247
1942 ± 751
1827 ± 574
Protein (g)
82 ± 41
69 ± 31
76 ± 27
Carbohydrate (g)
283 ± 171
256 ±89
226 ± 76
Fat (g)
85 ± 60
60 ± 25
73 ± 27
Caffeine (g)
44 ± 86
50 ± 88
54 ± 91
FE Ratio 60o/s (%)
49.1 ± 11.3
50.4 ± 10.4
49.3 ± 8.3
FE Ratio 180o/s (%)
54.0 ± 11.3
56.7 ± 10.2
54.4 ± 9.8
FE Ratio 300o/s (%)
67.5 ± 14.0
68.3 ± 14.7
66.6 ± 12.5
Repetitions to Fatigue
40.6 ± 8.4
40.0 ± 8.7
39.3 ± 8.6
Rested Joint Laxity (mm)
6.7 ± 2.7
6.4 ± 2.3
6.1 ± 2.1
Fatigued Joint Laxity (mm)
6.9 ± 2.2
6.4 ± 2.3
6.4 ± 1.9
Data given as means ± SD. No significant differences among visits were observed. FE Ratio = Knee flexor-to-knee extensor ratio.

Table 5. Hormone concentrations by menstrual cycle phase.
Non-OC (n=22)a

P-Value
Early-Follicular Phase
Estradiol (pg/ml)
67 (22-110)
40 (18-81)
0.001
Progesterone (ng/ml)
0.05 (0.04-0.13)
0.04 (0.03-0.23)
NS
Relaxin (pg/ml)
24 (8-74)
22 (10-67)
NS
Ovulatory Phase
Estradiol (pg/ml)
121 (60-330)
33 (13-109)
<0.001
Progesterone (ng/ml)
0.32 (0.03-12.26)
0.04 (0.01-0.32)
<0.001
Relaxin (pg/ml)
22 (20-47)
22 (7-67)
NS
Mid-Luteal Phase
Estradiol (pg/ml)
148 (60-298)
29 (15-67)
<0.001
Progesterone (ng/ml)
1.04 (0.03-12.21)
0.04 (0.03-0.42)
<0.001
Relaxin (pg/ml)
27 (11-90)
24 (8-60)
NS
a
3 participants did not ovulate and were excluded from all analyses. b 1 participant did not have complete data from all analyses. All data
were log-normal distributed, therefore data are presented as geometric means (95% CI).

follicular visit (28.5±1.0 nM) compared to the ovulation
and luteal phase visits (32.6±1.0 nM and 33.0±1.0 nM,
respectively; both, p<0.05). Results were similar for
flexion peak torque at 300o/sec with 9-10% lower peak
torque being observed at the early-follicular phase visit
(28.4±1.2 nM) compared with the ovulation and luteal
phase visits (31.7±1.2 nM and 31.1±1.2 nM, respectively;
both p<0.05).
The group-by-phase interaction was not significant for
any of the extension or flexion peak torque measures, and
extension and flexion peak torque values were not different
between the OC and non-OC group at any visit (Supplemental
Table 2).
Knee flexor-to-knee extensor ratio at 60o, 180o and
300oo/second; repetitions to fatigue at 180o/second;
http://www.ismni.org

OC (n=24)b

and both rested and fatigued joint laxity did not change
throughout the menstrual cycle (Table 4).
Hormone concentrations
Hormone concentrations for the non-OC and OC groups
at each visit are given in Table 5. During the early-follicular
phase, participants in the non-OC group had higher
estradiol concentrations than the OC group, (p<0.001)
and progesterone concentrations did not differ. At both
the ovulatory and mid-luteal phase visits, estradiol and
progesterone concentrations were both higher in the nonOC group than the OC group (p<0.001 for all comparisons).
Relaxin concentrations did not differ between non-OC
and OC groups at any visit. Significant group-by-phase
interactions were observed for estradiol and progesterone
320
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with concentrations of both hormones becoming elevated in
the non-OC group after the early-follicular phase.

Discussion
The purpose of this study was to investigate changes in
muscular strength and stamina, measured by isokinetic
testing of the knee flexors and knee extensors, throughout
the menstrual cycle and to determine whether or not changes
were different between OC and non-OC users. The key
finding from the current study is that flexion and extension
isokinetic peak torques were lower in the early-follicular
phase than the ovulatory and mid-luteal phases during the
180o and 300o/sec testing. Additionally, during the 60o/sec
testing, peak torque was greater during the ovulatory phase
than the early-follicular phase. Particularly troubling in the
area of ACL injury prevention is the finding of 4-11% lower
flexion peak torque during the early-follicular phase of the
cycle. Given the role of the hamstrings in protecting against
anterior tibial translation, a decrease in hamstring strength
could place women in the early-follicular phase of their cycle
at a greater risk of suffering an ACL injury. The relationship
between ACL injury and hamstring strength has been shown
previously in a matched case-control study that found lower
hamstring strength in females who went on to tear their
ACL33. In addition to decreased lower extremity strength
during the early-follicular phase, grip strength also was lower
during the early-follicular phase than the ovulatory and midluteal phases. This is important because it indicates a whole
body effect rather than an isolated effect or learning effect.
The absence of a learning effect also is supported by previous
work that indicated a high level of test-retest reliability34 and
mechanical reliability32 with isokinetic measurements using
the Biodex System 4 and our results finding no change in
three measurements taken longitudinally over a 30-day
period (see Supplemental Table 1).
The findings from the present study are similar to findings
from a previous study that reported lower peak torque
production during leg extension and flexion during the
early-follicular phase compared to the ovulatory phase in
female soccer players35. In the study by Dos Santos et al.,
no differences were observed in males tested at the same
time intervals, and the authors suggested that the lower
peak torque during the early-follicular phase may be due to
hormonal effects that are specific to females. On the other
hand, a study similar to ours reported no phase-specific
differences in force, velocity, or power output during half
squats on a Smith machine36. One explanation for why these
findings could differ from ours could be that the nature of
isokinetic exercise requires greater muscle recruitment
than an isotonic movements such as a squat and therefore
may be more sensitive to small physiological changes in
neuromuscular performance.
Previous studies investigating injury risk throughout
the menstrual cycle have reported that risk of ACL injuries
are greater early in the menstrual cycle37 and in particular
http://www.ismni.org

prior to ovulation38,39. Decreased muscle strength could
potentially increase the risk of suffering an ACL injury and
our findings of lower peak torque in the early-follicular phase
may indicate a potential risk factor for ACL injuries. However,
it is important to note that other studies have reported ACL
injury risk to be greatest during the ovulatory phase which
is when the greatest torque production was observed in the
current study9,40.
Significant group-by-phase interactions were observed
for estradiol and progesterone with concentrations of both
hormones being elevated in the non-OC group after the
early-follicular phase. However, these hormonal fluctuations
did not appear to affect any of the outcome measures in this
study because no significant group-by-phase interactions
were observed. This finding is in agreement with a previous
study indicating no influence of reproductive hormones on
skeletal muscle contractility41. The finding of no difference
between the OC and non-OC groups in the study by de Jonge
et al. and the present study are somewhat surprising given
previously published work that reported a protective effect
of oral contraception on ACL injury risk24,25. However, it is
important to consider that hormonal fluctuations are not the
only physiological change throughout the menstual cycle.
In the absence of a hormone-related effect, one potential
explaination for lower skeletal muscle strength during the
follicular cycle is low iron concentrations. While this was not
measured in the present study, the negative effect of low
iron concentrations and the benefits of iron supplementation
in female athetes has been well documented in both
submaximal and maximal exercise42. It has previously been
reported that as many as 30% of all female collegiate
athletes are iron deficient43 and therefore any small decrease
in iron concentration due to menstrual bleeding could have
significant implications on neuromuscular performance.
Furthermore, one study indicated that iron concentrations
were lower during the early follicular phase than the ovulatory
phase44. If iron concentrations are lower during the early
follicular phase than the ovulatory or luteal phases, then
theoretically a decrease in maximal exercise performance
may be expected. Future studies should be performed to
determine if menstrual phase changes in musculoskeletal
performance can be attenuated by using supplemental iron.
Limitations
A limitation of this study is the reliance on each participant
completing maximal contractions during muscle testing.
We addressed this limitation by using the peak torque
measurement from a total of five repetitions rather than the
average peak torque. We also compared the coefficient of
variation among repetitions to determine if any participants
had a within-test variability that was outside the norm for
the entire sample. An additional limitation is that the study
only utilized a single menstrual cycle and each participant
began the study during the early-follicular phase. While this
may introduce the chance of a learning effect, this is not
likely based on findings from a reliability trial that showed no
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increases in isokinetic peak torque or grip strength among
three visits performed over 30 days (see Supplemental Table
1). Additionally, the percent difference among measurements
in the present study was greater than the coefficient of
variation previously observed in the reliability study for all
measurements except the 60o/second isokinetic peak torque
where the percent difference between the early-follicular and
ovulation phases was smaller than the percent CV.

Conclusion
In conclusion, grip strength and peak torque were lower
during the early-follicular phase than the ovulatory and
mid-luteal phases. A surpising finding was that changes in
peak torque and grip strength throughout the cycle were
similar regardless of whether or not the female was taking
oral contraceptives. Given the role of oral contraceptives in
stabilizing hormone concentrations throughout the cycle,
the results of this study indicate that cycle phase dependent
differences in strength may not be explained by sex hormone
fluctuations. Future studies investigating the role of other
hormones or non-hormonal factors as it relates to ACL
risk factors throughout the menstrual cycle are necessary
to determine appropriate strategies for attenuating the
strength deficits observed in the present study.
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Supplemental Table 1. Reliability of grip strength and isokinetic peak torque.
Baseline Mean1
CV2
r3
p-value4
Grip Strength
44.7 ± 15.9 kg
4.4
0.04
0.96
Ext. Peak Torque 60o/sec
150.1 ± 55.2 Nm
6.8
0.08
0.89
Ext. Peak Torque 180o/sec
103.3 ± 31.2 Nm
5.8
0.09
0.83
Ext. Peak Torque 300o/sec
80.8 ± 22.2 Nm
6.2
0.12
0.78
Joint Laxity
5.8 ± 1.8 mm
4.3
0.01
0.99
1
Data are means ± SD at the baseline visit. 2Percent coefficient of variation. 3Correlation-coefficient for the relationship between outcome
measures and visit. 4P-value for the correlation between outcome measures and visit number.

Supplemental Table 2.

Grip Strength (kg)
Extension Peak Torque
60o/sec (Nm)
180o/sec (Nm)
300o/sec (Nm)
Flexion Peak Torque
60o/sec (Nm)
180o/sec (Nm)
300o/sec (Nm)

http://www.ismni.org

Early-Follicular
Non-OC
OC
30.2 ± 4.2
29.9 ± 4.7

Ovulatory
Non-OC
OC
31.9 ± 3.7
31.1 ± 4.5

Mid-Luteal
Non-OC
OC
32.9 ± 5.0
32.9 ± 5.0

80.6 ± 16.1
51.8 ± 9.9
41.2 ± 9.5

84.1 ± 13.2
55.4 ± 9.4
44.5 ± 7.6

84.7 ± 15.8
55.6 ± 10.7
44.1 ± 9.1

86.7 ± 13.9
60.4 ± 10.2
48.3 ± 8.9

83.9 ± 16.5
58.9 ± 11.5
45.5 ± 9.3

85.4 ± 12.2
61.8 ± 9.8
47.6 ± 8.1

37.5 ± 6.7
26.8 ± 7.9
27.4 ± 7.7

42.0 ± 11.2
30.7 ± 6.8
30.2 ± 8.0

43.9 ± 15.9
30.3 ± 7.7
28.0 ± 7.4

42.0 ± 7.5
34.9 ± 6.8
34.9 ± 9.7

40.6 ± 9.3
30.7 ± 6.9
29.0 ± 7.6

42.2 ± 8.5
34.2 ± 6.9
33.1 ± 7.0
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